Icrucumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Icrucumab
Monoclonal antibody
Type Whole antibody
Source Human
Target VEGFR-1
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
Formula C6514H10024N1756O2032S42
Molar mass 146.8 kg/mol
 NYesY (what is this?)  (verify)

Icrucumab is a human monoclonal antibody designed for the treatment of solid tumors.[1]

Icrucumab was developed by ImClone Systems Inc.

References[edit]

  1. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Icrucumab" (PDF). American Medical Association.